NOAH Compendium

Printed from NOAH Compendium ( (c) Copyright NOAH Compendium 2019. All Rights Reserved.
Date: Wednesday, May 22, 2019 11:00

Telephone: 01908 685685 (Customer Support Centre)
Release 2.18
Species: Sheep
Therapeutic indication: Immunological veterinary medical products: For sheep
Active ingredient: Vaccine Antigens
Product:Toxovax® Concentrate and diluent for suspension for injection for sheep
Product index: Toxovax
Sheep - meat: 42 days
Live, concentrated vaccine containing ≥ 105 tachyzoites of the S48 strain of Toxoplasma gondii per dose. Unisolve® is supplied as a diluent for dilution prior to use.
For the active immunisation of susceptible breeding female sheep to reduce the effects of infection by Toxoplasma gondii, namely early embryonic death, barrenness and abortion.
Vaccination with Toxovax is known to protect for at least two lambing seasons.
Dosage and administration
The vaccine is supplied as a liquid concentrate containing 20 or 50 doses. Immediately before use this is added to the diluent (Unisolve 40 or 100 ml, respectively), giving a dose volume of 2 ml.
Injection equipment
To minimise the risk of self-injection the vaccine should be administered using disposable automatic syringes fitted with the Sterimatic guarded needle system according to the manufacturer's instructions.
An administration kit including a vented transfer device for vaccine reconstitution and disposable automatic syringe with the Sterimatic guarded needle system is available from the company.
It is vital that a vented draw off tube is used with this equipment. Regular checks should be made to ensure the syringes are properly calibrated.
Carefully attach the vial of reconstituted vaccine to the injection equipment and avoid creating aerosols during the priming process. It may be advisable to wear a visor while carrying out this operation.
Protective gloves (impervious rubber or plastic such as disposable medical gloves or surgical gloves (EU guidelines)) and goggles or a face visor should be worn when reconstituting the vaccine.
If using the vented transfer device push one end of the device through the centre of the Unisolve vial using a firm, twisting action. Similarly, push the vaccine vial onto the opposite end of the device taking care to ensure the spike penetrates the centre of the vial bung. The vaccine concentrate will drain into the diluent vial. Remove the empty vaccine vial and transfer spike from the diluent vial and place into an appropriate disinfectant solution.
Alternatively, withdraw the entire contents of the vaccine concentrate vial using a sterile disposable 10 ml syringe and either a 16 g or 18 g sterile needle. Carefully expel any air from the syringe and inject the contents into the diluent vial. With the diluent vial upright withdraw 5-10 ml of air prior to removing the needle. This maintains the vial under negative pressure and avoids spillage when the needle is removed.
After dilution the vaccine should be kept cool and away from light and used as soon as possible (within 2 hours). Ideally only dilute one vaccine vial at a time.
Dose: 2 ml by intramuscular injection.
Basic vaccination
Animals should be given a single dose at least 3 weeks prior to mating. Ewe lambs, where it is intended to breed from them, may be vaccinated from 5 months of age. Shearlings and older ewes should be vaccinated during the 4 month period prior to mating.
Re-vaccination After 2 years, a single dose at least 3 weeks prior to mating.
Contra-indications, warnings, etc
Do not vaccinate animals less than 3 weeks before mating.
Do not use during pregnancy.
A transient temperature rise is normally observed (up to 41 °C, returning to normal within 7-8 days of vaccination).
At 20 times dose no particular signs, other than a transient temperature increase similar to that seen with a single dose (although up to 41.5 - 42 °C) have been observed.
Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with Enzovax (Vm 01708/4523). It should be given at separate sites.
No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except Enzovax. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Do not mix with any other veterinary medicinal product except the diluent Unisolve supplied for use with the product.
Toxoplasma is only one of the causes of abortion in sheep. Where abortion occurs in sheep which have been vaccinated with Toxovax then it is recommended that veterinary advice is sought immediately to clarify the likely cause.
Care should be taken in handling such abortions as susceptible humans may be at risk of infection.
A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immuno-competence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.
Only healthy animals should be vaccinated.
Operator warnings
Toxovax should not be handled by pregnant women, or women of child-bearing age as the vaccine may interfere with normal foetal development.
Toxovax should not be handled by persons who are immunodeficient (e.g. AIDS sufferers; persons undergoing chemotherapy or taking immunosuppressive drugs).
Operators should wear gloves when handling the vaccine.
Living tachyzoites can cause disease in man.
Care should be taken to avoid self-injection and to avoid vaccine getting into the mouth or the eyes. In the case of self-injection, immediate medical advice should be sought and the doctor should be informed that self-injection with a living tachyzoite toxoplasma vaccine has occurred. Pyrimethamine therapy is the current recognised treatment for toxoplasmosis in humans.
Withdrawal period
Meat and offal: 42 days.
For animal treatment only. Keep out of the sight and reach of children.
Pharmaceutical precautions
Store and transport refrigerated (+2 °C to +8 °C). Protect from light. Do not freeze.
After dilution the vaccine should be kept cool and away from light and used as soon as possible (within 2 hours).
Disposal advice
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant, in accordance with local requirements.
Legal category
Legal category: POM-V
Packaging quantities
Carton with 1 vial of vaccine, 1 vial of Unisolve and one transfer kit.
Vials containing 10, 20 or 50 doses supplied together with Unisolve.
Not all pack sizes may be marketed.
An administration kit including a vented transfer device for vaccine reconstitution and disposable automatic syringe with a guarded needle system is available.
Further information
Marketing Authorisation Number
Vm 01708/4331
Significant changes
GTIN description:Toxovax 20 dose:
GTIN description:Toxovax 50 dose: